New LaunchNov 12, 2026, 09:01 AM
Alps Group Launches Pharmaco-Interaction Lab via MyGenome Subsidiary
AI Summary
Alps Group Inc announced the launch of its Pharmaco-Interaction (PCI) laboratory unit through its MyGenome subsidiary. The new unit will offer CYP450 inhibitory IC50 testing, a service recommended by the FDA and EMA for evaluating drug interactions. This launch positions MyGenome as a reference laboratory in Southeast Asia for drug interaction safety science, catering to the region's growing herbal and botanical products industry and aiming to establish Malaysia as a hub for ethical life science services.
Key Highlights
- Alps Group Inc launched its Pharmaco-Interaction (PCI) laboratory unit within its MyGenome subsidiary.
- The PCI unit will offer CYP450 inhibitory IC50 testing for seven major enzyme isoforms.
- This service supports safe use, regulatory compliance, and consumer confidence for drugs and botanical products.
- PCI aims to become Southeast Asia's reference laboratory for drug interaction safety science.
- The service is available to herbal and supplement manufacturers, pharmaceutical companies, and research institutions.
Price Impact
More from ALPS